Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination.
about
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaThe thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2.Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells.Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localizationAdult human sarcomas. II. Medical oncology.Thrombospondin-based antiangiogenic therapy.A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments.Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapiesTumor angiogenesis: insights and innovations.Therapies using anti-angiogenic peptide mimetics of thrombospondin-1.Antiangiogenic and anticancer molecules in cartilage.Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.Negative regulators of angiogenesis: important targets for treatment of exudative AMD.Thrombospondins: A Role in Cardiovascular Disease.Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors.Aiding and ABT'ing Treatment for Glioblastoma.Thrombospondins function as regulators of angiogenesis.ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis.Thrombospondin-1 is a multifaceted player in tumor progression.
P2860
Q26747666-18073531-286A-49CB-9ED2-FC73A2B2CE3EQ33727047-B584D0EB-6ED9-48E6-976E-8B1BA7765480Q35902676-012AAFE0-9E15-4918-8E40-473AE00990C4Q36496361-6A66F343-58AE-4A19-B825-6893627FF9D7Q36578825-383FA37F-EFAA-47FE-B251-0CB2FBA137F5Q36731430-E15EA1FD-CC5D-4F92-BF6F-C847205680C3Q36845405-52863707-94DF-4502-AB45-D511F0FE7946Q36977417-834AA310-4001-4D8C-B3EA-D0B3CE13927BQ37294120-D621CF0A-120F-45E1-82B3-2EC60C38BC37Q37385797-02C53172-2D90-47C9-BF55-D72E578B4C97Q37743207-A60A8327-2E31-4B15-8A58-26D1184E37E9Q37963916-FE9A085E-8ED7-446B-BEF4-E7507F6562F3Q38007565-C042D176-64B9-4689-A861-B17B95A3FDB8Q38974266-719EAFE2-BC95-4240-85D4-3FA759B2E085Q39416208-E2EA5534-AED1-4DBA-9148-CBD3FCFE6368Q39438819-BE02BEEF-6088-48A4-9749-9000E8F91E4FQ39725116-F3512895-FD33-4A0E-94A0-0DD44E6949A9Q42324168-F5A98418-2C10-4789-BA4F-CFB6A6F98DAAQ42643939-112FCE8D-37D2-4B46-AA20-DAA99CA914A5Q43104986-D009D62E-A513-40FB-AD5A-CD437A1F21E4Q47120215-47816BAC-147E-4D6D-B062-F9F58EC826AA
P2860
Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Phase I study of the thrombosp ...... eucovorin: a safe combination.
@en
Phase I study of the thrombosp ...... eucovorin: a safe combination.
@nl
type
label
Phase I study of the thrombosp ...... eucovorin: a safe combination.
@en
Phase I study of the thrombosp ...... eucovorin: a safe combination.
@nl
prefLabel
Phase I study of the thrombosp ...... eucovorin: a safe combination.
@en
Phase I study of the thrombosp ...... eucovorin: a safe combination.
@nl
P2093
P1476
Phase I study of the thrombosp ...... leucovorin: a safe combination
@en
P2093
Hoekstra R
Humerickhouse R
P304
P356
10.1016/J.EJCA.2005.08.040
P577
2006-01-10T00:00:00Z